Navigation Links
Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
Date:3/12/2008

TSX: BMR

TORONTO, March 12 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a clinical oncology company specializing in the development and commercialization of cancer therapies, today announced its 2007 fourth quarter and fiscal year operational and financial results.

Operational Highlights

During the year ended December 31, 2007, the Company achieved the following steps in preparation for the upcoming multi-center Phase III trial and subsequent planned commercialization for its lead drug Neuradiab, a treatment for glioblastoma multiforme, the most deadly form of brain cancer:

- Completed development and validation of cGMP manufacturing processes

of the Neuradiab drug substance (antibody component) and final drug

product (radiolabeled antibody).

- Conducted pre-Phase III meetings with the U.S. Food and Drug

Administration (FDA) regarding the protocol and design of the Phase

III trial as well as the drug manufacturing processes.

- Entered formal contracting and approval processes with more than 30

U.S. clinical trial sites, in line with previously stated site

recruitment goals.

- Prepared and submitted the Company's drug manufacturing data package

to the FDA, subsequent to the end of the fiscal year. The submission

is currently under review. After completion of the review and

satisfactory resolution of any further requests of the FDA, if any,

Bradmer will submit a clinical update to its Investigational New Drug

(IND) application and proceed with the launch of the planned Phase

III trial.

"We have made significant progress toward the initiation of our planned multi-center Phase III trial of Neuradiab by focusing specifically on reducing risk in the critical areas of manufacturing, regulatory and clinical operations," said Alan M. Ezrin, Ph.D
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Notice of Bradmer Pharmaceuticals Conference Call
2. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
3. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
4. Bradmer announces additions to Scientific Advisory Board
5. Bradmer Medical Isotope Supply For Phase III Trial Secure
6. Bradmer to present at Rodman & Renshaw Healthcare Conference
7. Bradmer provides Phase III Neuradiab trial update and guidance
8. Bradmer announces management changes
9. NHP Announces Management Promotions
10. WellPoint Announces Appearances at Upcoming Conferences
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Lehman Brothers Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 04, 2015 The American ... G. Thomopulos, P.E., Chairman of Stanley Consultants , ... board of directors for a three-year term. , ACEC ... and the American Society of Civil Engineers (ASCE). ... rating system for civil infrastructure called Envision. Launched in ...
(Date:5/4/2015)... 2015 Malibu Biotech Systems LLC ... spray. KissSafe™ is the first personal hygiene product ... while adding fresh breath appeal. KissSafe™ contains an ... germs in the mouth and oral cavity before ... that possess additional wellness benefits. KissSafe’s proprietary prevent-tech ...
(Date:5/4/2015)... Leonardo J. Lozada, M.D., Saint Luke’s Health ... William C. Daniel, M.D., Saint Luke’s Health System chief ... the Secretary of the Air Force to attend the ... War College, Maxwell Air Force Base, Alabama. The purpose ... U.S. and international officers and their civilian counterparts in ...
(Date:5/4/2015)... SACRAMENTO, Calif. (PRWEB) May 04, 2015 ... Permanente Medical Group today launched a new initiative ... building the next generation of physicians committed to ... Estudiantes Para Ser Medicos, or Preparing Students to ... multi-faceted initiative that will provide scholarships, mentorship and ...
(Date:5/4/2015)... New York, New York (PRWEB) May 04, 2015 ... as much as $2.4 billion to settle thousands of ... Type 2 diabetes medication increases the risk that a ... documents issued on April 28th, if 95% of those ... accord will resolve nearly 9,000 bladder cancer cases currently ...
Breaking Medicine News(10 mins):Health News:Thomopulos Appointed to Institute for Sustainable Infrastructure Board 2Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2Health News:Saint Luke’s Health System Leadership Selected to Attend National Security Forum 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 4Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 5Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3
... of a two-year clinical trial that Avastin, a drug approved ... to treat age-related macular degeneration (AMD), is as effective as ... of AMD. The report, from the Comparison ... New England Journal of Medicine on Sunday, May ...
... DETROIT A new Henry Ford Hospital study takes a ... most serious side-effects of ACE inhibitor use facial, tongue ... invasive course of treatment. Using a treatment ... and promptly treated to reduce swelling, resulting in no tracheotomies ...
... release is available in French and Spanish ... have proven that melatonin a natural hormone produced by the ... intake of food, improves blood lipid profile as it reduces ... is found in small quantities in some fruits and vegetables ...
... April 28, 2011 The first World Congress of Pediatric ... together the largest and most successful international congregation of pediatric ... Journal of Urology and the Journal of ... at this meeting. The vitality of clinical and ...
... , THURSDAY, April 28 (HealthDay News) -- Women are ... undergoing a common heart imaging test called coronary angiography, a ... contrast dye is used to enhance images of the heart,s ... kidney,s blood vessels to narrow, damaging the organ, explained Dr. ...
... , WEDNESDAY, April 27 (HealthDay News) -- If you suffer a ... severe than having one at any other time of day, a ... happens between 6 a.m. and noon, it is likely to damage ... in the afternoon or evening, the researchers added. "It is ...
Cached Medicine News:Health News:NIH study finds Avastin and Lucentis are equally effective in treating AMD 2Health News:NIH study finds Avastin and Lucentis are equally effective in treating AMD 3Health News:NIH study finds Avastin and Lucentis are equally effective in treating AMD 4Health News:Study targets treatment for serious ACE inhibitor side effect 2Health News:Melatonin might help in controlling weight gain and preventing heart diseases associated with obesity 2Health News:Success of First World Congress of Pediatric Urology underscores increasing importance of specialty 2Health News:Women's Kidneys May Be at Higher Risk After Heart Test 2Health News:Morning Heart Attacks Cause More Damage, Study Finds 2Health News:Morning Heart Attacks Cause More Damage, Study Finds 3
(Date:5/4/2015)... May 4, 2015 RadiologyAuction will have their first ... and product demonstrations at the end of the auction ... as Kodak and Fuji Cr,s, Agfa and Sony, printers ... first event. Various imaging equipment will be available at ... After years of buying and selling imaging equipment, ...
(Date:5/4/2015)... 2015 Rogne Bioscience, a privately-held biotechnology company ... preclinical and mechanism of action data will be presented ... Dermatology (SID) Annual Meeting being held May 6-9, 2015 ... . Logo - http://photos.prnewswire.com/prnh/20150501/213318LOGO ... a novel, low MW (<1700 daltons) peptide as a ...
(Date:5/4/2015)... -- Bayer HealthCare (Bayer) has entered into an exclusive ... ) on ISIS-FXI Rx, an antisense investigational drug ... the agreement Bayer will further develop and commercialize ISIS-FXI ... As part of the clinical development program, Bayer plans ... in an appropriate patient community. "Bayer is ...
Breaking Medicine Technology:RadiologyAuction Announces Event Starting On May 5th 2Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
... SINGAPORE , UPPSALA, Sweden and CANTON, Mass. , ... that the US Food and Drug Administration (FDA) has given the ... Mesh, for use in reinforcement of soft tissues where weakness exists. ... synthetic matrix, knitted from two different resorbable fibers that degrade at ...
... SAN FRANCISCO, Calif. , Feb. 5 Poniard Pharmaceuticals, Inc. ... today announced that Ronald Martell , chief executive officer, will provide ... on Tuesday, February 9, 2010 at 1:00 p.m. Eastern ... . , A live audio webcast of the corporate overview will be ...
Cached Medicine Technology:Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - World's 1st Long-Term Resorbable Synthetic Mesh 2Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - World's 1st Long-Term Resorbable Synthetic Mesh 3Poniard Pharmaceuticals to Present at 12th Annual BIO CEO and Investor Conference 2
Straight heavy shafts with delicate 7 mm tying platform. Sharp pointed tips for removing fine sutures. Wide serrated handle with polished finish. Overall length 4.1 inches....
Angled 45 degree shafts with 10.5 mm tying and 1 mm of tip crisscross serrated. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.2 inches....
Curved, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Titanium. Straight shafts with 6.5 mm tying platform. Round knurled handle with dull finish. Overall length 4.4 inches....
Medicine Products: